Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00366522
NCT00366522
Completed
Phase 1

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 sitesAugust 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy
DrugsLXR-623

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Primary Endpoint
Safety and Tolerability
Status
Completed
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Registry
clinicaltrials.gov
Start Date
August 2006
End Date
September 2006
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Safety and Tolerability

Similar Trials

Completed
Phase 1
Study Evaluating LXR-623 in Healthy Japanese AdultsHealthy
NCT00385489Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Phase 1
A Safety Study of LY3462817 in Healthy ParticipantsHealthy
NCT03715192Eli Lilly and Company64
Terminated
Phase 1
Study Evaluating HTC-867 in Healthy Young and Elderly SubjectsHealthy Subjects
NCT00827489Wyeth is now a wholly owned subsidiary of Pfizer72
Withdrawn
Phase 1
Study Evaluating Single Doses of GAP-134Healthy Subjects
NCT00820521Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Phase 1
Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy SubjectsHealthy
NCT00550381Wyeth is now a wholly owned subsidiary of Pfizer72